Choline Transporter Inhibito 1PC X 10MG

Code: 5339170001 D2-231

Biochem/physiol Actions

Reversible: yes

Primary TargetCHT

Cell permeable: yes

General description

A moderately brain permeant, non-ch...


read more

Your Price
€150.20 EACH
€184.75 inc. VAT

Biochem/physiol Actions

Reversible: yes

Primary TargetCHT

Cell permeable: yes

General description

A moderately brain permeant, non-choline based isoxazolylbenzamide compound that acts as a highly selective and potent inhibitor of high-affinity choline transporter (CHT; Ki = 92 nM in hCHT-LV-AA transfected HEK293 cells and 166 nM in mouse brain synaptosomes). The inhibition appears to be allosteric and noncompetitive. Does not affect the activity of acetylcholinesterase or cholineacetyltransferase and has no activity against dopamine, serotonin, and norepinephrine transporters. Also does not affect CHT protein expression. Exhibits high selectivity when tested against 68 GPCRs, ion channels, and transporters (IC50 >10 µM). Displays moderate pharmacokinetic properties (t1/2= 33 min, AUC = 77.5 ng/h/ml; Cmax = 32.6 ng/ml, at 2.3 mg/kg, p.o. in Sprague-Dawley rats) and attractive solubility (98.2 µM in PBS). Does not affect the activity of cytochrome P450 and hERG (IC50 >30 µM).

A cell-permeable pyridinylpropanylthiophene-carboxamide compound that exhibits selective affinity toward MT/microtubule-bound KIFC1 motor domain (Q305-K673; Kd = 690 nM), but not to uncomplexed KIFC1 or MT, and selectively inhibits MT-induced, but not basal, KIFC1 motor domain ATPase activity (IC50 = 300 nM; [KIFC1] = 30 nM, [MT] = 100 nM, [ATP] = 15 µM) in an ATP-competitive (Ki = 43 nM; [KIFC1] = 125 nM, [MT] = 1.5 µM) and MT-noncompetitive manner, effectively preventing ADP release, while displaying little potency against 9 other kinesin motor proteins (﹤15% or no inhibition at 5 µM against human CENP-E, Chromokinesin/KIF4A, Eg5, KIFC3, KIF3C, KInesin Heavy Chain/KIF5B, MCAK/KIF2C, MKLP1/KIF23, and A. nidulans BimC/KIF8). KIFC1 knockdown by siRNA or functional inhibition by AZ82 (0.4 to 1.2 µM) is shown to result in mitotic delay and multipolar spindle formation among BT549 population with extra centrosomes due to failure of chromosomes clustering. In cells with normal/two centrosomes, Eg5 inhibition causes monopolar spindles formation, while AZ82 co-treatment (400 nM) offsets the effect of Eg5 inhibition (5 nM AZD4877) and restores bipolar spindles phenotype in mitotic HeLa cells. Off-target cytotoxicity is reported when used at concentrations above 4 µM.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Ennis, E.A., et al. ACS Chem. Neurosci.6, In press.

Packaging

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)

assay≥97% (HPLC)
colorbrown
formsolid
manufacturer/tradenameCalbiochem®
Quality Level100
solubilityDMSO: 50 mg/mL
storage conditionprotect from light, OK to freeze
storage temp.2-8°C
Cas Number1649450-12-3
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.